Recent Visitors 10

GRASSROOT Trial Stroke Device Brings New Hope to India

Newz Daddy Health Care Updates

“Marengo CIMS Hospital Highlights India’s Breakthrough Homegrown Stroke Device Validated by the Landmark GRASSROOT Trial”

India has taken a decisive step forward in advanced stroke treatment with the successful completion of the GRASSROOT Trial, a landmark multicentre clinical study evaluating the Supernova Stent Retriever for patients with acute ischemic stroke due to large vessel occlusion. This achievement marks a major milestone in India’s journey toward self-reliance in advanced neurovascular care, a field traditionally dominated by imported medical devices.

At the core of this breakthrough lies the fact that “Stent design by indian engineers and study done in indian 8 hospital, including CIMS hospital and going to make in India dream come true.” The GRASSROOT Trial was conducted across eight leading stroke centres in the country, including Marengo CIMS Hospital, providing strong clinical data from Indian patients. Such trials are vital, as stroke patterns, access to care, and treatment timelines in India often differ from Western settings where most global studies are conducted.

Adding to its national significance, this innovation confirms that “Made in India stent now for brain vessels also in acute brain stroke.” Until now, most devices used for mechanical thrombectomy in India were imported and costly, limiting access for many patients. The Supernova stent retriever has shown encouraging results, including high rates of vessel reopening, good first-pass success, and positive recovery outcomes at 90 days, all while maintaining a low rate of complications.

These results are important because time is critical in stroke care. Every minute of delay can lead to the loss of millions of brain cells. Mechanical thrombectomy has become a gold-standard treatment for large vessel strokes worldwide, but its reach in India has been limited. An effective, locally developed device can help more hospitals offer this life-saving procedure without the heavy financial burden of imported tools.

Highlighting the clinical impact, Dr Mukesh Sharma, Principal Investigator of the Trial, Director, Neurointervention & Stroke, Marengo CIMS Hospital, said, “The GRASSROOT Trial is a game-changer for stroke care in India.” His remarks underline how improved access to proven technology can help doctors act faster, especially in smaller cities and resource-limited settings where advanced stroke care is still developing.

Dr R. Shankaran, Unit Medical Director, Marengo CIMS Hospital, added that the study proves world-class outcomes are possible with indigenous innovation. His statement reflects a growing confidence among Indian clinicians that locally designed medical devices can meet global safety and performance standards while being better suited to Indian healthcare realities.

Emphasising the broader cardiovascular ecosystem, Dr Keyur Parikh, Interventional Cardiologist and Chairman, Marengo CIMS Hospital, noted the urgent need for scalable and cost-effective solutions for complex emergencies. Stroke often strikes without warning, and many patients reach hospitals late. Affordable, reliable devices can help expand treatment availability and improve survival and recovery rates across the country.

Underscoring Marengo CIMS Hospital’s commitment to excellence, Dr Raajiv Singhal, Founding Member, Managing Director and Group CEO, highlighted the hospital group’s patient-first approach. He stressed that innovation must be rooted in real-world outcomes, solid evidence, and trust. His comments also pointed to the importance of collaboration between doctors, engineers, and institutions in building a sustainable healthcare ecosystem.

With India witnessing nearly 1.7 million new stroke cases every year, the burden on families and the healthcare system is immense. Many survivors live with long-term disability, affecting their livelihoods and quality of life. Indigenous, evidence-based innovations like the Supernova stent retriever offer hope by strengthening acute stroke care and reducing dependence on costly imports.

As India continues to push towards self-reliance in healthcare technology, the success of the GRASSROOT Trial stands as a strong example of what can be achieved when clinical expertise, engineering skill, and patient needs come together. Marengo CIMS Hospital’s role in this journey highlights how Indian hospitals are not only adopting global best practices but also helping shape the future of medical innovation at home.